Skip to main content

PMV Pharmaceuticals, Inc.

PMVP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001699382

No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q3 2026, worth $94.4M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$99.0M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +1 vs. previous quarter
64
13F valueReported value at the end of Q3 2026
$94.4M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$77.7M
No comparable prior period
Free cash flow, FY2025
-$73.6M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
2.15M
Shares sold short
Change
−131.5K
−5.8% vs. previous
Days to cover
5.62
At average daily volume

Superinvestors holding PMVP, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding PMVP at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by PMV Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 27, 2025 (view filing)5:19 PM ETOct 234 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−1.00M$1.52−$1.52M−16.7%4.98M after
Sep 12, 2025 (view filing)5:09 PM ETSep 102 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−500.0K$1.80−$900.0K−7.7%5.98M after
Jul 3, 2025 (view filing)Jul 12 daysTicktin RobertGeneral Counsel & COOSSale−23.2K$1.06−$24.5K−19.0%98.7K after
Jul 3, 2025 (view filing)Jul 12 daysJalota DeepikaChief Development OfficerSSale−33.1K$1.06−$35.0K−26.9%90.0K after
Jul 3, 2025 (view filing)Jul 12 daysCarulli MichaelChief Financial OfficerSSale−28.2K$1.06−$29.9K−32.0%60.1K after
Jul 3, 2025 (view filing)Jul 12 daysMack David HenryPresident and CEOSSale−58.4K$1.06−$61.9K−9.8%536.1K after
Sep 12, 2024 (view filing)Sep 111 dayJalota DeepikaChief Development OfficerSSale−7.22K$1.50−$10.8K−5.8%118.3K after
Sep 12, 2024 (view filing)Sep 111 dayCarulli MichaelChief Financial OfficerSSale−2.89K$1.50−$4.34K−3.2%88.4K after
Nov 24, 2023 (view filing)4:38 PM ETNov 222 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−87.8K$2.23−$195.8K−100.0%0 after
Sep 18, 2023 (view filing)Sep 153 daysJalota DeepikaChief Development OfficerSSale−4.10K$6.62−$27.2K−12.1%29.9K after

Top 10 13F holders, Q3 2026

See all 64 holders

The largest institutional positions in PMV Pharmaceuticals, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding PMVP in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BML Capital Management, LLC7,330,000$12.2M6.57%+2,000,000+37.5%Added
Tang Capital Management LLC7,285,085$12.2M0.56%+3,040,000+71.6%Added
Samsara BioCapital, LLC7,240,000$12.1M1.15%+7,240,000New
Sio Capital Management, LLC3,634,137$6.07M1.29%+1,000,000+38.0%Added
Vanguard Capital Management LLC3,083,667$5.15M0.00%+1,071,647+53.3%Added
ADAR1 Capital Management, LLC2,700,349$4.51M0.19%+2,499,341+1,243.4%Added
Euclidean Capital LLC2,627,643$4.39M1.36%00.0%Unchanged
Two Sigma Investments, LP2,429,330$4.06M0.00%+475,194+24.3%Added
Adage Capital Partners GP, L.L.C.2,360,000$3.94M0.01%00.0%Unchanged
Acadian Asset Management LLC2,285,479$3.81M0.00%+69,585+3.1%Added

Holders of 5% or more of PMVP

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of PMV Pharmaceuticals, Inc..

Largest holders of PMVP from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Tang Capital Management LLC13G/A9.99%7.57M shares+1.09 ppfrom 8.90%Sep 23, 20252 filingsNov 16, 2026SEC
Samsara BioCapital, L.P.13G9.90%7.58M sharesNewSep 15, 20261 filingSep 15, 2026SEC
BML Investment Partners, L.P.13G/A9.90%5.29M shares+3.20 ppfrom 6.70%Dec 12, 20244 filingsFeb 9, 2026SEC